X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (149) 149
humans (126) 126
monoclonal-antibody (67) 67
double-blind (56) 56
animals (55) 55
evolocumab amg 145 (47) 47
pharmacology & pharmacy (47) 47
monoclonal antibodies (44) 44
subtilisin/kexin type 9 (42) 42
heterozygous familial hypercholesterolemia (41) 41
male (41) 41
oncology (40) 40
antibodies, monoclonal - therapeutic use (39) 39
female (39) 39
statins (39) 39
density-lipoprotein cholesterol (35) 35
low density lipoproteins (35) 35
hypercholesterolemia (34) 34
amg 145 (33) 33
amg 102 (32) 32
care and treatment (31) 31
middle aged (31) 31
cardiac & cardiovascular systems (30) 30
cholesterol (28) 28
treatment outcome (27) 27
analysis (24) 24
clinical trials (24) 24
adult (23) 23
aged (23) 23
cancer (23) 23
placebo-controlled trial (23) 23
c-met (22) 22
cholesterol, ldl - blood (22) 22
drug therapy (22) 22
hepatocyte growth-factor (22) 22
lipids (22) 22
medicine & public health (22) 22
health aspects (21) 21
pcsk9 (21) 21
antibodies, monoclonal - administration & dosage (20) 20
risk factors (20) 20
article (19) 19
proprotein convertase 9 (19) 19
proprotein convertase 9 - antagonists & inhibitors (19) 19
cardiovascular disease (18) 18
coronary-heart-disease (18) 18
review (18) 18
safety (18) 18
research (17) 17
antibodies, monoclonal - adverse effects (16) 16
cardiovascular diseases (16) 16
ldl-c (16) 16
medical research (16) 16
mice (16) 16
molecular targeted therapy (16) 16
amg (15) 15
anticholesteremic agents - therapeutic use (15) 15
clinical trials as topic (15) 15
hypercholesterolemia - drug therapy (15) 15
lipoproteins (15) 15
medicine, research & experimental (15) 15
physiological aspects (15) 15
biochemistry & molecular biology (14) 14
cardiovascular (14) 14
ldl cholesterol (14) 14
mutation (14) 14
proprotein convertase subtilisin/kexin type 9 (14) 14
antibodies, monoclonal - pharmacology (13) 13
atherosclerosis (13) 13
cardiology (13) 13
cell biology (13) 13
dyslipidemias - drug therapy (13) 13
pharmacokinetics (13) 13
proprotein convertases - antagonists & inhibitors (13) 13
statin therapy (13) 13
efficacy (12) 12
endocrinology & metabolism (12) 12
evolocumab (12) 12
expression (12) 12
familial hypercholesterolemia (12) 12
low density lipoprotein (12) 12
metastasis (12) 12
pharmacology (12) 12
proto-oncogene proteins c-met - antagonists & inhibitors (12) 12
subtilisin (12) 12
tumors (12) 12
abridged index medicus (11) 11
amg 386 (11) 11
angiogenesis (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
bevacizumab (11) 11
combination (11) 11
dosage and administration (11) 11
kexin (11) 11
met (11) 11
patients (11) 11
randomized controlled-trial (11) 11
receptor (11) 11
aged, 80 and over (10) 10
anticholesteremic agents (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 15, pp. 2936 - 2944
BACKGROUND Activation of the mesenchymal‐epidermal transition factor (MET) tyrosine kinase and its ligand, hepatocyte growth factor (HGF), is implicated in... 
amphiregulin | non–small cell lung cancer (NSCLC) | mesenchymal‐epidermal transition factor (c‐MET) | epidermal growth factor receptor (EGFR) | erlotinib | hepatocyte growth factor (HGF) | rilotumumab (AMG 102) | neuregulin 1 | mesenchymal-epidermal transition factor (c-MET) | 1ST-LINE TREATMENT | MONOCLONAL-ANTIBODY | OPEN-LABEL | non-small cell lung cancer (NSCLC) | ONCOLOGY | COLORECTAL-CANCER | C-MET | 2ND-LINE TREATMENT | DOUBLE-BLIND | RESISTANCE | MUTATIONS | EXPRESSION | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Erlotinib Hydrochloride - administration & dosage | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Squamous Cell - secondary | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Cancer patients | Care and treatment | Erlotinib | Gene mutations | Lung cancer, Small cell | Dosage and administration | Research | Health aspects | Adenocarcinoma | Neuregulin 1 | Mesenchyme | Lung cancer | Criteria | Amphiregulin | K-Ras protein | Metastases | c-Met protein | Confidence intervals | Cell activation | Epidermal growth factor | Safety engineering | Neuregulin | Safety | Protein-tyrosine kinase | Tyrosine | Epidermal growth factor receptors | Hepatocyte growth factor | Non-small cell lung carcinoma | Resistance factors | Disease control | Patients | Survival | Sensitivity | Biomarkers | Solid tumors | Tumors | Cancer
Journal Article
Journal Article
BJU International, ISSN 1464-4096, 09/2011, Volume 108, Issue 5, pp. 679 - 686
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | AMPLIFICATION | PHARMACOKINETICS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CANCER | EXPRESSION | CARCINOMA | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Drug Discovery Today, ISSN 1359-6446, 2009, Volume 14, Issue 1, pp. 56 - 67
Journal Article
Journal Article
ONCOTARGET, ISSN 1949-2553, 09/2017, Volume 8, Issue 38, pp. 63014 - 63025
Targeted therapeutic agents, such as inhibitors of epithelial growth factor receptor (EGFR), have transformed the management of non-small cell lung cancer... 
GEFITINIB | ADVANCED SOLID TUMORS | NSCLC | HGF | HEPATOCYTE GROWTH-FACTOR | ACQUIRED-RESISTANCE | EGFR MUTATIONS | LUNG-CANCER CELLS | CELL BIOLOGY | TYROSINE KINASE INHIBITORS | AMPLIFICATION | AMG 102 | MET | EPITHELIAL OVARIAN
Journal Article
Journal Article